Kerstin Gude
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study.
Journal: BMC women's health
Published: December 05, 2023
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
Journal: Drugs in R&D
Published: May 28, 2023
Surgical Outcomes in Patients With Endometriosis: A Systematic Review.
Journal: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
Published: March 18, 2019
Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study.
Journal: Journal of women's health (2002)
Published: October 31, 2017
Reevaluating response and failure of medical treatment of endometriosis: a systematic review.
Journal: Fertility and sterility
Published: December 26, 2016
Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.
Journal: Journal of pediatric and adolescent gynecology
Published: August 10, 2016
0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.
Journal: Climacteric : the journal of the International Menopause Society
Published: May 23, 2015
Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
Journal: Menopause (New York, N.Y.)
Published: August 22, 2013
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Journal: Menopause (New York, N.Y.)
Published: August 22, 2013
One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Journal: Climacteric : the journal of the International Menopause Society
Published: March 28, 2013
An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.
Journal: Menopause (New York, N.Y.)
Published: January 10, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026